Revion retatrutide is a research-grade triple agonist peptide sold for lab study only. Learn how it works, dosing debates, safety, and legal status in the US.
Revion retatrutide is a vendor-branded, research-grade version of retatrutide, an experimental triple-agonist peptide that has not been approved by the FDA for human use. It is sold as a lyophilized powder for laboratory and animal research, not as a prescription weight-loss medication. Anyone searching for it should treat it as an unapproved research chemical rather than a finished drug.
What Is Revion Retatrutide?
Revion is a brand name used by a supplier, not a different molecule. The active compound is retatrutide, also known as LY3437943, a single peptide engineered to activate three receptors at once: GLP-1, GIP, and glucagon.
Because the brand name only tells you who packaged the vial, the questions that matter are about purity, third-party testing, and cold-chain handling. The label on the box is the least useful piece of information.
- Form: lyophilized powder, commonly 5 mg or 10 mg per vial
- Reconstitution: bacteriostatic water, then refrigerated
- Stated use: laboratory research only, not for human consumption
How Retatrutide Works in the Body
Retatrutide is a triple agonist, meaning one molecule triggers three separate hormone pathways. GLP-1 activation slows gastric emptying and reduces appetite. GIP activation appears to improve how the body handles glucose and stored fat.
Glucagon receptor activation raises energy expenditure, and that third mechanism is the main reason researchers study retatrutide separately from dual agonists such as tirzepatide.
In published phase 2 trials, adults receiving weekly retatrutide injections lost substantial amounts of weight over 48 weeks. Those results come from a monitored clinical trial setting, not from self-administered research vials purchased online.
Retatrutide Dosage: What the Trials Actually Used
There is no official retatrutide dosage for humans, because no regulator has approved the drug for any indication. In the phase 2 obesity trial, participants were randomized to 1 mg, 4 mg, 8 mg, or 12 mg once weekly.
Doses were escalated gradually over several weeks to limit gastrointestinal side effects. Online discussion of retatrutide dosage frequently skips that titration step, which is exactly where most avoidable harm happens.
Clinicians who study these compounds consistently note that self-experimentation with unapproved peptides carries real risk of nausea, vomiting, rapid heart rate, pancreatitis, and gallbladder disease. Anyone weighing that risk should speak with a licensed healthcare professional first.
How Revion Retatrutide Compares With Other Peptides
Retatrutide sits in a crowded field of incretin-based compounds, which is why so many people search for cagrilintide vs retatrutide vs tirzepatide before deciding what to read about. The table below shows where each compound actually differs.
| Compound | Receptor targets | FDA status | Research notes |
|---|---|---|---|
| Retatrutide | GLP-1, GIP, glucagon | Not approved | Triple agonist; phase 3 trials ongoing |
| Tirzepatide (Mounjaro, Zepbound) | GLP-1, GIP | Approved | Dual agonist with a label and dosing guidance |
| Semaglutide (Ozempic, Wegovy) | GLP-1 | Approved | Single agonist, most studied of the group |
| Cagrilintide | Amylin | Not approved alone | Studied mainly in combination with semaglutide |
| AOD-9604 | HGH fragment 176-191 | Not approved | Fat-metabolism research peptide, no incretin activity |
The practical takeaway is that cagrilintide vs retatrutide is a comparison of two very different mechanisms: amylin signaling versus triple incretin and glucagon signaling. Only tirzepatide and semaglutide in that group have passed FDA review.
Stacking Retatrutide With Other Peptides
Because retatrutide already hits three receptors, stacking it with another appetite-suppressing peptide is a popular but poorly studied idea. Protocols that combine aod 9604 with retatrutide, or that pair cjc 1295 ipamorelin with retatrutide, rest on theory rather than published human data.
AOD-9604 is a fragment of human growth hormone studied for fat metabolism, while CJC-1295 with ipamorelin is a growth-hormone secretagogue combination. Neither has been tested alongside retatrutide in a controlled human trial.
When a supplier sells these compounds as a bundled kit, treat the marketing claims with skepticism. Adding more unapproved peptides multiplies unknown interactions without adding any proven benefit.
Safety, Legality, and Sourcing Risks
Retatrutide is not FDA-approved for human use in the United States, and selling it as a drug is illegal. Vials labeled for research use only sit in a gray zone that gives buyers little legal or medical protection.
Independent testing has repeatedly found that some research peptides are underdosed, mislabeled, or contaminated with unrelated compounds. A certificate of analysis from an accredited lab is a reasonable starting point, but it is not a guarantee of what is inside the vial.
Reported side effects in trials include nausea, diarrhea, constipation, and injection-site reactions. More serious concerns include pancreatitis and gallbladder disease. People who are pregnant or breastfeeding, or who have a history of pancreatitis or medullary thyroid cancer, should avoid these compounds entirely.
Questions to Ask Before You Buy
- Does the supplier publish a batch-specific, third-party certificate of analysis?
- Is the product shipped cold, and does the label clearly say research use only?
- Can the company explain what the Revion brand actually refers to?
- Is a physician involved who can order labs and monitor side effects?
Bottom Line on Revion Retatrutide
Revion retatrutide is a branded research peptide, not an approved medication, and the brand name adds no clinical value. The underlying molecule is genuinely interesting to scientists, but the retail versions sold online are unregulated, untested in humans at those sources, and legally risky to use.
Anyone curious about retatrutide for weight management should start with a conversation with a licensed healthcare professional about approved options. Research chemicals are not a shortcut around that step.
Frequently Asked Questions
Is Revion retatrutide FDA-approved?
No. Retatrutide has not been approved by the FDA for any human use, and no product sold under the Revion brand name is FDA-approved either. Vials sold online are labeled for laboratory research only. Selling or marketing them as a weight-loss drug is illegal in the United States.
What retatrutide dosage was used in clinical trials?
In the phase 2 obesity trial, participants received 1 mg, 4 mg, 8 mg, or 12 mg once weekly by injection. Doses were increased gradually over several weeks to reduce gastrointestinal side effects. There is no officially approved human dosage because the drug is still experimental.
Can retatrutide be stacked with other peptides like AOD-9604 or CJC-1295?
There is no published human trial testing retatrutide with AOD-9604, CJC-1295, or ipamorelin. Stacking unapproved peptides increases the chance of unknown interactions and side effects without any proven added benefit. A doctor should review any combination before it is considered.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.